GlobeNewsWire
09 Jun 2026, 16:47 UTC · 23w ago
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
Impact · against what's priced in
The survival data for masitinib in ALS is a significant positive catalyst, demonstrating a five-year survival rate of 42.3% against a benchmark of ~24%. The ability of nearly half of these survivors to maintain functional independence increases the probability of regulatory success and commercial viability.
- AB+0.70
No priced-in read yet





